Associations between the LEP -2548G/A Promoter and Baseline Weight and between LEPR Gln223Arg and Lys656Asn Variants and Change in BMI z Scores in Arab Children and Adolescents Treated with Risperidone
- PMID: 30397599
- PMCID: PMC6206968
- DOI: 10.1159/000490463
Associations between the LEP -2548G/A Promoter and Baseline Weight and between LEPR Gln223Arg and Lys656Asn Variants and Change in BMI z Scores in Arab Children and Adolescents Treated with Risperidone
Abstract
Data on baseline (antipsychotics-naïve) age, weight, and height, and change in these at 3 subsequent follow-up time points up to 313.6 days (95% CI 303.5-323.7) were collected from 181 risperidone-treated children and adolescents (mean age 12.58 years, SD 4.99, range 2.17-17.7) attending a pediatric neurology clinic in Saudi Arabia. Owing to differences in genotypic distributions in the subsamples, results are reported for the white Arab population (n = 144). Age- and gender-normed body mass index (BMI)-standardized z scores (BMI z) were calculated (LMSgrowth program). Linear regression was performed for baseline weight and BMI z, while change in BMI z was assessed using random effects ordered logistic regression. The following single nucleotide polymorphisms (SNPs) were analyzed: rs7799039 in the LEP promoter, rs1805094 (previously rs8179183), rs1137100 and rs1137101 in the LEPR, and rs1414334 in HTR2C. We found a nominally significant association between rs7799309 and baseline weight, adjusting for height, age, gender, and diagnosis (A/G, p = 0.035, β = -3.62 vs. G/G). The rs1137101 (G/G, p = 0.018, odds ratio [OR] = 4.13 vs. A/A) and rs1805094 C allele carriers (p = 0.019, OR = 0.51) showed nominally significant associations with change in BMI z categories. Our data support and replicate previous relevant associations for these variants (including with weight gain when on risperidone), whilst being the first report of such associations in patients of Arab ethnicity.
Keywords: Adolescent; Antipsychotic agents; Biomarker; Child; Genetics; Leptin; Leptin receptor; Pharmacogenetics; Polymorphism; Weight gain.
Figures
Similar articles
-
Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs.J Pharm Pharmacol. 2018 Apr;70(4):536-542. doi: 10.1111/jphp.12892. Epub 2018 Feb 13. J Pharm Pharmacol. 2018. PMID: 29441581
-
[Metabolic side effects of risperidone in early onset schizophrenia].Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. Encephale. 2010. PMID: 20620267 French.
-
Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.Psychiatr Genet. 2009 Dec;19(6):320-7. doi: 10.1097/ypg.0b013e3283328e06. Psychiatr Genet. 2009. PMID: 19873684 Free PMC article.
-
Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain.Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):134-41. doi: 10.1016/j.pnpbp.2012.03.001. Epub 2012 Mar 8. Prog Neuropsychopharmacol Biol Psychiatry. 2012. PMID: 22426215
-
Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis.Prog Neuropsychopharmacol Biol Psychiatry. 2020 Aug 30;102:109952. doi: 10.1016/j.pnpbp.2020.109952. Epub 2020 Apr 23. Prog Neuropsychopharmacol Biol Psychiatry. 2020. PMID: 32335267
Cited by
-
A study to investigate genetic factors associated with weight gain in people with diabetes: analysis of polymorphisms in four relevant genes.Adipocyte. 2023 Dec;12(1):2236757. doi: 10.1080/21623945.2023.2236757. Adipocyte. 2023. PMID: 37582184 Free PMC article.
References
-
- Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15:139–150. - PubMed
-
- Almandil NB, Wong IC. Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed. 2011;96:192–196. - PubMed
-
- Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69((suppl 4)):26–36. - PubMed
-
- Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008;121:1002–1009. - PubMed
-
- Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H, Wolf PA. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care. 1997;20:1388–1395. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous